Treatment of inflammatory diseases with mesenchymal stem cells
- PMID: 19530993
- DOI: 10.2174/187152809788462635
Treatment of inflammatory diseases with mesenchymal stem cells
Abstract
Human mesenchymal stem cells (hMSCs) are rare progenitor cells present in adult bone marrow that have the capacity to differentiate into a variety of tissue types, including bone, cartilage, tendon, fat, and muscle. In addition to multilineage differentiation capacity, MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component. The availability of bone marrow and the ability to isolate and expand hMSCs ex vivo make these cells an attractive candidate for drug development. The low immunogenicity of these cells suggests that hMSCs can be transplanted universally without matching between donors and recipients. MSCs universality, along with the ability to manufacture and store these cells long-term, present a unique opportunity to produce an "off-the-shelf" cellular drug ready for treatment of diseases in acute settings. Accumulated animal and human data support MSC therapeutic potential for inflammatory diseases. Several phase III clinical trials for treatment of acute Graft Versus Host Disease (GVHD) and Crohn's disease are currently in progress. The current understanding of cellular and molecular targets underlying the mechanisms of MSCs action in inflammatory settings as well as clinical experience with hMSCs is summarized in this review.
Similar articles
-
Therapeutic Potential of Mesenchymal Stem Cells in Immune-Mediated Diseases.Adv Exp Med Biol. 2019;1201:93-108. doi: 10.1007/978-3-030-31206-0_5. Adv Exp Med Biol. 2019. PMID: 31898783 Review.
-
Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease.Stem Cell Res Ther. 2015 Oct 23;6:202. doi: 10.1186/s13287-015-0197-8. Stem Cell Res Ther. 2015. PMID: 26497134 Free PMC article.
-
Immunosuppressive properties of mesenchymal stem cells: advances and applications.Curr Mol Med. 2012 Jun;12(5):574-91. doi: 10.2174/156652412800619950. Curr Mol Med. 2012. PMID: 22515979 Review.
-
Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?Front Immunol. 2020 Dec 11;11:609063. doi: 10.3389/fimmu.2020.609063. eCollection 2020. Front Immunol. 2020. PMID: 33362797 Free PMC article. Review.
-
Immune effects of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease.Cell Immunol. 2008 May-Jun;253(1-2):11-5. doi: 10.1016/j.cellimm.2008.06.003. Epub 2008 Jul 15. Cell Immunol. 2008. PMID: 18627903 Review.
Cited by
-
Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy.Stem Cells Transl Med. 2012 Jul;1(7):557-65. doi: 10.5966/sctm.2012-0025. Epub 2012 Jul 9. Stem Cells Transl Med. 2012. PMID: 23197860 Free PMC article.
-
Mesenchymal stromal cell characteristics vary depending on their origin.Stem Cells Dev. 2013 Oct 1;22(19):2606-18. doi: 10.1089/scd.2013.0016. Epub 2013 Jun 22. Stem Cells Dev. 2013. PMID: 23676112 Free PMC article.
-
In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment.Tissue Eng Part B Rev. 2014 Feb;20(1):28-39. doi: 10.1089/ten.TEB.2013.0100. Epub 2013 Jul 11. Tissue Eng Part B Rev. 2014. PMID: 23678952 Free PMC article. Review.
-
DPSCs from Inflamed Pulp Modulate Macrophage Function via the TNF-α/IDO Axis.J Dent Res. 2016 Oct;95(11):1274-81. doi: 10.1177/0022034516657817. Epub 2016 Jul 6. J Dent Res. 2016. PMID: 27384335 Free PMC article.
-
Mesenchymal Stromal Cells from the Maternal Segment of Human Umbilical Cord is Ideal for Bone Regeneration in Allogenic Setting.Tissue Eng Regen Med. 2017 Oct 25;15(1):75-87. doi: 10.1007/s13770-017-0086-6. eCollection 2018 Feb. Tissue Eng Regen Med. 2017. PMID: 30603536 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical